NYSE$IBIO
iBio Inc · Q2 2025 earnings
Q2 2025 earnings · · Investor relations
Briefing
iBio reported financial results for the second quarter ended December 31, 2024.
iBio reported revenue of $0.2 million for services provided to a collaborative partner and a net loss of $4.4 million, or $0.48 per share, for the second quarter ended Dec. 31, 2024. The company also highlighted advancements in its preclinical pipeline and key board appointments.
- Discovered a novel antibody targeting activin E in collaboration with AstralBio.
- Expanded iBio’s cardiometabolic and obesity program with IBIO-600, the long-acting anti-myostatin antibody in-licensed from AstralBio.
- Initiated a bispecific antibody program targeting myostatin/activin A to promote weight loss, muscle preservation, and prevent weight regain with plans for clinical investigation in obesity and cardiometabolic disorders in 2026.
- Strengthened the Board of Directors with the appointments of biotech industry veterans David Arkowitz and António Parada.
Headline financials
Revenue & EPS history
iBio · Revenue · Quarterly
$200K
Forward guidance
iBio is focused on leveraging its AI-driven platform to transform the treatment landscape for patients with cardiometabolic diseases and obesity.
Tailwinds
- Potential for IBIO-600 to be best-in-class.
- Leveraging iBio’s AI-driven platform to transform the treatment landscape for patients with cardiometabolic diseases and obesity.
- Offering hope for more effective, targeted therapies addressing the underlying causes of these conditions while improving overall metabolic health and quality of life.
- IBIO-600’s potential for an extended half-life.
- The creation of a pipeline of breakthrough antibody treatments to address significant unmet medical needs.
Headwinds
- iBio’s ability to leverage its AI-driven platform to transform the treatment landscape for patients with cardiometabolic diseases and obesity.
- iBio's ability to extend the half-life of IBIO-600.
- iBio's ability to advance as a clinical-stage biotech and commence a clinical investigation in obesity and cardiometabolic disorders in 2026.
- iBio's ability to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs.
- iBio's ability to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2025
-1.4%
Avg return
Earnings day
-2.9%
Avg return
5 days after
+14.3%
Avg return
30 days after
43%
17 / 40 earnings
Positive
+24.4%
Q3 2020
Best reaction
-34.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +12.9% | +9.9% | +22.8% | |
| Q1 2026 | -8.0% | -3.2% | +55.2% | |
| Q4 2025 | +3.7% | +8.6% | +6.2% | |
| Q3 2025 | +1.3% | +1.3% | +30.4% | |
| Q2 2025 | -14.8% | -7.8% | +49.2% | |
| Q1 2025 | -9.4% | -10.9% | -2.0% | |
| Q4 2024 | -2.6% | -4.2% | +51.1% | |
| Q3 2026 | -3.7% | +23.9% | +36.2% | |
| Q3 2024 | +1.6% | +7.0% | +37.8% | |
| Q2 2024 | +5.2% | +5.2% | +2.6% | |
| Q1 2024 | -3.4% | -10.3% | -78.1% | |
| Q4 2023 | -3.3% | -9.1% | -6.1% | |
| Q3 2023 | -7.9% | -5.9% | -31.7% | |
| Q2 2023 | -10.5% | +55.8% | +113.7% | |
| Q1 2023 | +0.0% | -8.6% | -68.6% | |
| Q4 2022 | -34.4% | -46.9% | -74.6% | |
| Q3 2022 | +0.0% | +0.0% | +12.0% | |
| Q2 2022 | +2.7% | -8.1% | -5.4% | |
| Q1 2022 | -9.2% | -11.8% | -17.1% | |
| Q4 2021 | -4.3% | -11.1% | -35.0% | |
| Q3 2021 | -6.8% | -0.7% | +5.4% | |
| Q2 2021 | -15.3% | -17.8% | -29.8% | |
| Q1 2021 | +15.2% | -9.6% | -38.2% | |
| Q3 2020 | +24.4% | +16.0% | +31.9% | |
| Q2 2020 | -10.5% | -21.1% | +321.1% | |
| Q1 2020 | +13.3% | -26.7% | +46.7% | |
| Q3 2019 | +7.3% | -2.4% | -4.9% | |
| Q2 2019 | -2.2% | -4.4% | -6.7% | |
| Q1 2019 | +4.0% | +9.3% | -10.7% | |
| Q1 2015 | +3.4% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q1 2013 | -1.9% | — | — | |
| Q3 2012 | -9.8% | — | — | |
| Q1 2010 | +1.8% | — | — | |
| Q1 2012 | +1.8% | — | — | |
| Q4 2011 | -3.0% | — | — | |
| Q3 2011 | +4.8% | — | — | |
| Q2 2010 | +3.4% | — | — | |
| Q4 2010 | +1.4% | — | — | |
| Q3 2010 | -1.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro